N Masuda

3.5k total citations
81 papers, 2.8k citations indexed

About

N Masuda is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, N Masuda has authored 81 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 56 papers in Oncology, 33 papers in Molecular Biology and 29 papers in Pulmonary and Respiratory Medicine. Recurrent topics in N Masuda's work include Lung Cancer Research Studies (37 papers), Lung Cancer Treatments and Mutations (20 papers) and Cancer therapeutics and mechanisms (19 papers). N Masuda is often cited by papers focused on Lung Cancer Research Studies (37 papers), Lung Cancer Treatments and Mutations (20 papers) and Cancer therapeutics and mechanisms (19 papers). N Masuda collaborates with scholars based in Japan, United Kingdom and United States. N Masuda's co-authors include Shuichiro Hirano, M. Fukuoka, Kunihiko Matsui, Shunichi Negoro, Nobuhide Takifuji, H Niitani, Kazuhiko Nakagawa, S. Kudoh, M Takada and Y Kusunoki and has published in prestigious journals such as Journal of Clinical Oncology, Applied and Environmental Microbiology and JNCI Journal of the National Cancer Institute.

In The Last Decade

N Masuda

74 papers receiving 2.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
N Masuda Japan 29 1.9k 1.7k 801 469 270 81 2.8k
Martin G. Belinsky United States 33 2.7k 1.4× 1.5k 0.9× 340 0.4× 289 0.6× 777 2.9× 51 4.2k
François Lokiec France 30 1.3k 0.6× 1.8k 1.1× 358 0.4× 226 0.5× 178 0.7× 143 3.3k
Subhankar Chakraborty United States 28 963 0.5× 1.1k 0.7× 387 0.5× 293 0.6× 473 1.8× 75 2.6k
Kazuhiro Katayama Japan 30 1.4k 0.7× 1.3k 0.7× 300 0.4× 665 1.4× 500 1.9× 136 3.3k
Manuel González-Barón Spain 26 1.3k 0.7× 2.1k 1.2× 486 0.6× 199 0.4× 246 0.9× 55 3.8k
David Chang United States 25 1.4k 0.7× 1000 0.6× 415 0.5× 164 0.3× 465 1.7× 68 2.9k
L. Austin Doyle United States 21 3.8k 2.0× 2.3k 1.3× 284 0.4× 217 0.5× 618 2.3× 39 5.0k
José Luís Zamora Manzano Spain 26 1.3k 0.6× 890 0.5× 557 0.7× 172 0.4× 254 0.9× 106 2.2k
Francesco Torino Italy 25 1.4k 0.7× 985 0.6× 439 0.5× 392 0.8× 257 1.0× 95 3.0k
Pengfei Yu China 27 726 0.4× 1.2k 0.7× 436 0.5× 439 0.9× 795 2.9× 137 2.9k

Countries citing papers authored by N Masuda

Since Specialization
Citations

This map shows the geographic impact of N Masuda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by N Masuda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites N Masuda more than expected).

Fields of papers citing papers by N Masuda

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by N Masuda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by N Masuda. The network helps show where N Masuda may publish in the future.

Co-authorship network of co-authors of N Masuda

This figure shows the co-authorship network connecting the top 25 collaborators of N Masuda. A scholar is included among the top collaborators of N Masuda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with N Masuda. N Masuda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Masuda, N, et al.. (2025). Characteristics of dry eye associated with autoimmune diseases. Japanese Journal of Ophthalmology. 69(2). 188–195.
2.
3.
Nakahara, Yoshiro, Yusuke Takagi, Kageaki Watanabe, et al.. (2015). 437P Activity of S-1 for non-small cell lung cancer pretreated with pemetrexed. Annals of Oncology. 26. ix125–ix125.
4.
Maemondo, Makoto, N Masuda, Ikuo Sekine, et al.. (2009). A phase II study of palonosetron combined with dexamethasone to prevent nausea and vomiting induced by highly emetogenic chemotherapy. Annals of Oncology. 20(11). 1860–1866. 48 indexed citations
5.
Negoro, Shunichi, N Masuda, Y Takada, et al.. (2003). Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer. British Journal of Cancer. 88(3). 335–341. 121 indexed citations
6.
Masuda, N. (2001). Establishment of the standard regimen for non-small-cell lung cancer in Japan.. PubMed. 15(1 Suppl 1). 13–8. 1 indexed citations
7.
Kageyama, Shinji, Kazuyo Fujita, Kazuo Suzuki, et al.. (2000). Effect of age on the responses of rat bladder detrusor strips to adenosine triphosphate. British Journal of Urology. 85(7). 899–904. 15 indexed citations
8.
Takeda, Koji, Shunichi Negoro, S. Kudoh, et al.. (1999). Phase I/II study of weekly irinotecan and concurrent radiation therapy for locally advanced non-small cell lung cancer. British Journal of Cancer. 79(9-10). 1462–1467. 35 indexed citations
9.
Matsui, K, N Masuda, M. Fukuoka, et al.. (1998). Phase II trial of carboplatin plus oral etoposide for elderly patients with small-cell lung cancer. British Journal of Cancer. 77(11). 1961–1965. 39 indexed citations
10.
Fukuoka, M., N Masuda, Shunichi Negoro, et al.. (1997). CODE chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer. British Journal of Cancer. 75(2). 306–309. 37 indexed citations
11.
Masuda, N, et al.. (1997). Different effect of anticholinergic agents and potassium channel openers on urinary bladder response to pelvic nerve stimulation in anaesthetized dogs. Journal of Autonomic Pharmacology. 17(2). 91–96. 7 indexed citations
12.
Takada, M, Y Kusunoki, N Masuda, et al.. (1996). Pro-gastrin-releasing peptide(31-98) as a tumour marker of small-cell lung cancer: comparative evaluation with neuron-specific enolase. British Journal of Cancer. 73(10). 1227–1232. 54 indexed citations
13.
Takada, M, N Masuda, Eiji Matsuura, et al.. (1995). Measurement of cytokeratin 19 fragments as a marker of lung cancer by CYFRA 21-1 enzyme immunoassay. British Journal of Cancer. 71(1). 160–165. 68 indexed citations
14.
Masuda, N, M. Fukuoka, Satoshi Kudoh, et al.. (1994). Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer.. Journal of Clinical Oncology. 12(1). 90–96. 78 indexed citations
15.
Masuda, N, M. Fukuoka, S. Kudoh, et al.. (1993). Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer. British Journal of Cancer. 68(4). 777–782. 85 indexed citations
16.
Masuda, N, M. Fukuoka, M Takada, et al.. (1992). CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer.. Journal of Clinical Oncology. 10(11). 1775–1780. 130 indexed citations
17.
Fukuoka, M., H Niitani, Atsushi Suzuki, et al.. (1992). A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer.. Journal of Clinical Oncology. 10(1). 16–20. 374 indexed citations
18.
Negoro, Shunichi, M. Fukuoka, N Masuda, et al.. (1991). W-III-6 DOSE INTENSIVE WEEKLY CODE CHEMOTHERAPY (CT) WITH OR WITHOUT rhG-CSF IN EXTENSIVE-STAGE (ES) SMALL CELL LUNG CANCER (SCLC).. 31(5). 637.
19.
Fukuoka, M., N Masuda, Y Kusunoki, et al.. (1991). Phase I Study of Weekly Intravenous Infusions of CPT-11, a New Derivative of Camptothecin, in the Treatment of Advanced Non-Small-Cell Lung Cancer. JNCI Journal of the National Cancer Institute. 83(16). 1164–1168. 242 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Martin G. Belinsky Breakdown of academic impact, for papers by François Lokiec Breakdown of academic impact, for papers by Subhankar Chakraborty Breakdown of academic impact, for papers by Kazuhiro Katayama Breakdown of academic impact, for papers by Manuel González-Barón Breakdown of academic impact, for papers by David Chang Breakdown of academic impact, for papers by L. Austin Doyle Breakdown of academic impact, for papers by José Luís Zamora Manzano Breakdown of academic impact, for papers by Francesco Torino Breakdown of academic impact, for papers by Pengfei Yu
Rankless by CCL
2026